30-day readmission after point-of-care ultrasound in adults with type 2 diabetes: A multicentre observational study
Published
October 31, 2024
Paper ID
PAP-000247
Status
Published
DOI
10.65712/tmj.test000505
Advance Services
Abstract
Background: Guidelines make only a weak recommendation on point-of-care ultrasound. Methods: We conducted a multicentre observational study across 2 centres between 2019 and 2025. Results: Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.48 (95% CI 0.31 to 0.87). Conclusion: Residual confounding cannot be excluded.
References
1. Rossi P, Silva S, et al. Nurse-led discharge planning and medication adherence. BMC Med. 2018;225(9):589-1784.
2. Rahman C, Osei P, et al. Pharmacist-led medication review and health-related quality of life. BMC Med. 2020;86(3):755-1029.
3. Andersen X, Nasser A, et al. An antibiotic stewardship programme and length of stay. Eur Heart J. 2014;107(2):483-1641.
4. Volkov R, Larsen V, et al. Early mobilisation and medication adherence. BMJ. 2014;147(8):862-935.
5. Dubois U, Novak P, et al. Pharmacist-led medication review and length of stay. Diabetes Care. 2020;272(2):632-1628.
Introduction
Guidelines make only a weak recommendation on point-of-care ultrasound. The cost of 30-day readmission to health systems is substantial. Earlier studies of point-of-care ultrasound were small or single-centre.
Practice around point-of-care ultrasound varies widely between centres. Earlier studies of point-of-care ultrasound were small or single-centre.
Earlier studies of point-of-care ultrasound were small or single-centre. Guidelines make only a weak recommendation on point-of-care ultrasound.
Practice around point-of-care ultrasound varies widely between centres. Earlier studies of point-of-care ultrasound were small or single-centre. 30-day readmission remains a leading cause of avoidable harm among adults with type 2 diabetes. The cost of 30-day readmission to health systems is substantial.
Materials and Methods
We conducted a multicentre observational study across 12 centres between 2017 and 2024. Analyses were adjusted for age, sex and baseline severity. Missing data were handled with multiple imputation. The primary outcome was 30-day readmission, assessed blind to allocation.
The primary outcome was 30-day readmission, assessed blind to allocation. Analyses were adjusted for age, sex and baseline severity. Missing data were handled with multiple imputation.
Results
Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups.
| Group | n | Events | Rate % | OR | 95% CI |
|---|---|---|---|---|---|
| Control | 314 | 98 | 6.9 | 0.44 | 0.58–1.37 |
| Age ≥ 65 | 67 | 108 | 4.2 | 0.75 | 0.59–1.31 |
| Age < 65 | 868 | 7 | 6.3 | 0.60 | 0.38–1.25 |
| Female | 126 | 77 | 18.3 | 0.57 | 0.54–1.32 |
| Centre A | 509 | 21 | 14.2 | 0.78 | 0.37–1.40 |
Values are n (%) unless stated otherwise.

Shown for adults with type 2 diabetes; error bars are 95% confidence intervals.
Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.55 (95% CI 0.27 to 0.70).
30-day readmission occurred in 19% of the intervention group versus 24% of controls. Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups.
Discussion
Residual confounding cannot be excluded. Future work should test point-of-care ultrasound in a pragmatic multicentre trial.
Residual confounding cannot be excluded. Strengths include the sample size and blinded outcome assessment.
Residual confounding cannot be excluded. Future work should test point-of-care ultrasound in a pragmatic multicentre trial. Implementation will depend on staffing, cost and local protocols.
Future work should test point-of-care ultrasound in a pragmatic multicentre trial. These findings suggest that point-of-care ultrasound is associated with better 30-day readmission in adults with type 2 diabetes.
Residual confounding cannot be excluded. These findings suggest that point-of-care ultrasound is associated with better 30-day readmission in adults with type 2 diabetes. Strengths include the sample size and blinded outcome assessment. Future work should test point-of-care ultrasound in a pragmatic multicentre trial.
Conclusions
Point-of-care ultrasound is a reasonable option for adults with type 2 diabetes to improve 30-day readmission.
Appendices
Ethics approval: IRB-5924.